BridgeBio Oncology Therapeutics (BBOT) Net Cash Flow (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Net Cash Flow for 3 years, with the latest figure at -$321.0 million in Q1 2026.

• Quarterly Net Cash Flow fell 6826.19% year-over-year to -$321.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$408.1 million (down 1782.76% YoY) and the FY2025 annual result came in at $342.8 million, up 1015.53% from the prior year.
• Net Cash Flow fell to -$321.0 million in Q1 2026 per BBOT's latest filing, from -$35.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $18.6 million in Q2 2025 and troughed at -$321.0 million in Q1 2026.
• A 3-year average of -$42.4 million and a median of -$29099.0 in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow soared 63901.0% in 2025, then slumped 6826.19% in 2026.
• Over 3 years, Net Cash Flow stood at $10.6 million in 2024, then sank by 431.54% to -$35.1 million in 2025, then tumbled by 815.81% to -$321.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$321.0 million, -$35.1 million, and -$70.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.